

# Antimicrobial Activity of DC-159a, a New Fluoroquinolone, against 1,149 Recently Collected Clinical Isolates<sup>▽</sup>

Ronald N. Jones,<sup>1,2\*</sup> Thomas R. Fritsche,<sup>1</sup> and Helio S. Sader<sup>1,3</sup>

JMI Laboratories, North Liberty, Iowa<sup>1</sup>; Tufts University School of Medicine, Boston, Massachusetts<sup>2</sup>; and Universidade Federal de São Paulo, São Paulo, Brazil<sup>3</sup>

Received 3 March 2008/Returned for modification 30 March 2008/Accepted 15 June 2008

The activity of DC-159a, a novel orally administered fluorinated quinolone, was evaluated by reference broth microdilution or agar dilution methods against 1,149 recently collected clinical isolates from five continents. Against pathogens associated with community-acquired respiratory tract infections (CA-RTIs), the MIC<sub>90</sub>s were 0.12 µg/ml for *Streptococcus pneumoniae*, 0.015 to 0.03 µg/ml for *Haemophilus influenzae*, 0.03 µg/ml for *Moraxella catarrhalis*, and 0.12 µg/ml for beta-hemolytic streptococci. Similarly, DC-159a was potent against various types of staphylococci (MIC<sub>90</sub> range, 0.03 to 2 µg/ml), *Enterococcus faecalis* (MIC<sub>90</sub>, 4 µg/ml), wild-type isolates of the family *Enterobacteriaceae* (MIC<sub>90</sub> range, 0.06 to 2 µg/ml), wild-type *Pseudomonas aeruginosa* (MIC<sub>90</sub>, 2 µg/ml), and *Acinetobacter* spp. (MIC<sub>90</sub>, 0.12 µg/ml). Fluoroquinolone-nonsusceptible organism subsets usually had elevated DC-159a MICs, but the MICs were often two- to fourfold lower than those of levofloxacin and moxifloxacin. In conclusion, DC-159a appears to possess a balanced broad spectrum of activity that exceeds the activities of the currently marketed fluoroquinolones, especially against pathogens that cause CA-RTIs.

The emergence of resistance among commonly isolated pathogens has compromised the clinical utility of several major antimicrobial classes, including the β-lactams, macrolides, aminoglycosides, glycopeptides, and fluoroquinolones (1, 7, 12, 14). For the fluoroquinolones, the modifications of the DNA gyrase and topoisomerase targets (7) can elevate the gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin MICs into the resistant ranges for *Streptococcus pneumoniae* isolates and, more rarely, *Haemophilus influenzae* and *Moraxella catarrhalis* isolates. Similarly, important gram-positive pathogens (staphylococci, beta-hemolytic streptococci, enterococci) and gram-negative bacilli (members of the family *Enterobacteriaceae*, *Pseudomonas* spp.) have consistently acquired resistance to the fluoroquinolones by prolonged exposure (1, 13, 14). The need for novel agents in this class has become critical for continued access to agents with clinical activity and for the provision of agents with a balance of potencies against species of emerging pathogens (multidrug-resistant [MDR] *Acinetobacter* spp. and *Stenotrophomonas maltophilia*) while offering continued coverage against pneumococci, *Staphylococcus aureus*, and other community-acquired pathogens (10, 13).

DC-159a is a novel orally administered fluoroquinolone developed by Daiichi Pharmaceutical Co., Ltd. (Tokyo, Japan), and has been reported to have a residual affinity for strains with mutations in the quinolone resistance-determining region (QRDR) (2, 9). Such features (10) provide this agent with a focus of activity against community-acquired pathogens that cause significant occurrences of respiratory tract infections, uncomplicated cutaneous infections, and possibly, other infections caused by wild-type members of the family *Enterobacte-*

*riaceae*. To assess this possibility, an international collection of recently collected gram-positive and -negative pathogens (1,149 strains) that contained organisms with well-characterized mechanisms of resistance or with the phenotypic expression of resistance according to the MICs was selected. All tests were performed by reference Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS) methods with appropriate medium supplements for fastidious streptococci (2 to 5% lysed horse blood) and *Haemophilus* sp. strains (*Haemophilus* test medium formulation) (3, 4).

(This paper was presented in part in posters F1-0479 and F1-0480 at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 2006.)

## MATERIALS AND METHODS

**Bacterial strains.** A total of 1,149 strains recently collected (2005 to 2007) from infected patients worldwide were studied, with a balance of isolates from Europe, the Asia-Pacific, and the Americas (North and South America). The following major species were sampled: *S. pneumoniae* (*n* = 112; 62 penicillin nonsusceptible), *Streptococcus pyogenes* (*n* = 30), *Streptococcus agalactiae* (*n* = 30), *Staphylococcus aureus* (*n* = 90; 60 methicillin-resistant *S. aureus* [MRSA] strains and 30 community-acquired *S. aureus* [CA-MRSA] strains), coagulase-negative staphylococci (CoNS; *n* = 60), enterococci (*n* = 173; 62 vancomycin-resistant enterococci and 10 linezolid-resistant enterococci), *Listeria monocytogenes* (*n* = 10), *H. influenzae* (*n* = 80; 30 β-lactamase-positive strains and 10 β-lactamase-negative and ampicillin-resistant [BLNAR] strains), *Haemophilus parainfluenzae* (*n* = 30), *M. catarrhalis* (*n* = 29; 19 β-lactamase-positive strains), *Bordetella pertussis* (*n* = 12), members of the family *Enterobacteriaceae* (*n* = 323; 38 species), *Pseudomonas aeruginosa* (*n* = 40), *Acinetobacter* spp. (*n* = 40; 5 species), *S. maltophilia* (*n* = 30), and *Neisseria gonorrhoeae* (*n* = 60; 40 ciprofloxacin-nonsusceptible strains). Numerous subsets of wild-type strains and strains with defined resistance mechanisms or phenotypes in each genus or species group were tested.

**Susceptibility testing methods.** DC-159a and levofloxacin standard powders were supplied by Daiichi Pharmaceutical Co., Ltd. All other agents were obtained from domestic (U.S.) manufacturers. The reference methods described by the CLSI were used throughout the study (3, 4). Gonococci were tested by the agar dilution method on GC agar base with the defined supplement (3, 4). The

\* Corresponding author. Mailing address: JMI Laboratories, 345 Beaver Creek Center, Suite A, North Liberty IA 52317. Phone: (319) 665-3370. Fax: (319) 655-3371. E-mail: ronald-jones@jmilabs.com.

<sup>▽</sup> Published ahead of print on 23 June 2008.

interpretive criteria of CLSI standard M100-S18 (4) were used, where available, to determine the susceptibilities of the isolates to the comparison agents (24 antimicrobials). The PCR methods described by Mutnick et al. (11) were used to determine the 23S rRNA mutations (G2576T) associated with the linezolid resistance found in the enterococci.

Quality control was ensured by the use of the following strains: *S. aureus* ATCC 29213, *Enterococcus faecalis* ATCC 29212, *Escherichia coli* ATCC 25922 and ATCC 35218, *P. aeruginosa* ATCC 27853, *H. influenzae* ATCC 49247 and ATCC 49766, *S. pneumoniae* ATCC 49619, and *N. gonorrhoeae* ATCC 49226. All quality control test results were within published CLSI ranges (4).

## RESULTS

When the 107 pneumococci were subcategorized by their susceptibilities to penicillin (Table 1), the DC-159a MIC<sub>90</sub> remained unaffected at 0.12 µg/ml. This potency was equal to that of moxifloxacin and eightfold greater than that of levofloxacin. The DC-159a MIC results for the levofloxacin-non-susceptible *S. pneumoniae* strains were generally increased 8- to 16-fold, but all MICs remained ≤2 µg/ml. Beta-hemolytic streptococci were very susceptible to DC-159a, with MIC<sub>50</sub>s and MIC<sub>90</sub>s of 0.12 µg/ml. This potency was slightly greater than that of moxifloxacin and eightfold greater than that of levofloxacin (MIC<sub>90</sub>, 1 µg/ml).

Most of the antimicrobials tested were active against the *H. influenzae* strains (Table 1). The exceptions were ampicillin against β-lactamase-producing strains, azithromycin (rate of nonsusceptibility, 2.5 to 3.4%), cefuroxime (2.5%), tetracycline (6.7%), and trimethoprim-sulfamethoxazole (20.0 to 22.5%). All fluoroquinolones were very active against *H. influenzae*, with MIC<sub>90</sub>s ranging from ≤0.015 to ≤0.12 µg/ml. The DC-159a MIC<sub>90</sub>s for the *H. influenzae* strains were 0.015 and 0.03 µg/ml, with the highest values being for the β-lactamase-positive isolates. The 10 BLNAR strains had very low DC-159a MICs that ranged from 0.008 to 0.015 µg/ml. The *H. parainfluenzae* strains were approximately fourfold less susceptible to DC-159a than the *H. influenzae* strains. This difference was also observed for the other fluoroquinolones tested (Table 1). The *M. catarrhalis* strains were very susceptible to DC-159a, with MIC<sub>50</sub>s and MIC<sub>90</sub>s of 0.03 µg/ml, regardless of whether they produced a β-lactamase (Table 1).

Table 2 lists the activity of DC-159a against 150 isolates of staphylococci. DC-159a exhibited potent activity against methicillin (oxacillin)-susceptible *S. aureus* (MSSA) strains, with MIC<sub>50</sub>s and MIC<sub>90</sub>s of only 0.03 µg/ml. This level of activity was 16-fold greater than that of ciprofloxacin but 2-fold less than that of gemifloxacin (MIC<sub>90</sub>, 0.015 µg/ml). MRSA strains derived from patients with nosocomial infections showed the greatest susceptibility to DC-159a (MIC<sub>90</sub>, 2 µg/ml). However, the range of DC-159a MICs was 32- to 64-fold greater than that for MSSA strains (0.015 to 0.06 µg/ml for MRSA strains versus 0.5 to 4 µg/ml for MSSA strains). None of these MRSA strains were susceptible at the CLSI breakpoint concentrations of the comparison, marketed fluoroquinolones. The activity of DC-159a against 30 well-characterized isolates from patients with CA-MRSA infection (USA300-0114 and its variants) was tested, and the MIC<sub>50</sub> and MIC<sub>90</sub> results for these strains were identical to those for the MSSA strains (Table 2). The CA-MRSA strains had a documented virulence island (Panton-Valentine leukocidin positive), staphylococcal chromosomal cassette *mec* type IVa, and *agrI*. Only 30% of the coagulase-negative staphylococcal strains were oxacillin susceptible, and

the DC-159a MICs ranged from 0.03 to 0.5 µg/ml (5 log<sub>2</sub> dilutions steps). The activity of DC-159a against a large number of *Staphylococcus saprophyticus* strains (*n* = 30) was tested, with complete activity being achieved at ≤0.5 µg/ml. Overall, among the five groups of staphylococci tested, DC-159a at ≤0.5 µg/ml inhibited all isolates in four of the groups (the exception was the nosocomial MRSA group). DC-159a showed a potency most similar to that of gemifloxacin (MIC<sub>90</sub> range, 0.016 to 2 µg/ml) and markedly greater than the potencies of the other fluoroquinolones tested.

With one exception, each group of enterococci tested (Table 2) contained a mixture of strains best described as wild type (DC-159a MIC range, ≤0.06 to 0.5 µg/ml) and drug-resistant mutants (DC-159a MIC range, 2 to >8 µg/ml). The DC-159a MIC of 1 µg/ml appears to separate these isolates into two groups that have modal MICs of 0.12 and 4 µg/ml, respectively. Eighty percent of the vancomycin-susceptible *E. faecalis* strains were ciprofloxacin susceptible (wild-type MIC distributions), and among these strains, the potency rank was as follows: gemifloxacin (MIC<sub>90</sub>, 0.03 µg/ml) > DC-159a (MIC<sub>90</sub>, 0.12 µg/ml) > gatifloxacin = moxifloxacin (MIC<sub>90</sub>, 0.25 µg/ml) > ciprofloxacin = levofloxacin (MIC<sub>90</sub>, 0.5 µg/ml). The largest number of mutant (fluoroquinolone-resistant) enterococcal phenotypes was encountered among the vancomycin-resistant isolates (53 of 62 strains) and the linezolid-resistant isolates (10 of 10 strains).

*E. coli* wild-type isolates (90% of which were susceptible to ciprofloxacin) were equally susceptible to DC-159a and levofloxacin (MIC<sub>50</sub>s, 0.03 µg/ml) (Table 3). In contrast, *E. coli* strains producing extended-spectrum β-lactamase (ESBL) enzymes were more likely to be fluoroquinolone resistant, and the DC-159a and levofloxacin MIC<sub>50</sub>s were 1 doubling dilution higher than those for the wild type (Table 2). The wild-type *Klebsiella* spp. were highly susceptible to ciprofloxacin (90% susceptible; MIC<sub>50</sub>s, ≤0.03 µg/ml) and DC-159a (MIC<sub>50</sub> range, 0.03 to 0.5 µg/ml). Ten *K. pneumoniae* strains harboring a KPC-type serine carbapenemase were tested (Table 3), and only two strains had DC-159a MICs of ≤2 µg/ml.

Table 3 also illustrates the activity of DC-159a against 20 *Proteus mirabilis* strains, 2 of which produced a CTX-M-type ESBL, as determined by molecular testing. DC-159a had activity (MIC<sub>50</sub>, 0.25 µg/ml) equal to the activities of gatifloxacin and moxifloxacin; but it was less active by weight (fourfold) than levofloxacin, gemifloxacin, and ciprofloxacin. With the current CLSI susceptibility breakpoints (4), susceptibilities of the *P. mirabilis* strains to the marketed fluoroquinolones showed marked variations (>20%), with the ranking being as follows: levofloxacin > gatifloxacin > ciprofloxacin > gemifloxacin (moxifloxacin does not have a published breakpoint).

Among the *Citrobacter* spp. (20 of 30 of the strains were *Citrobacter freundii* strains), *Enterobacter* spp. (26 of 33 of the strains were *Enterobacter cloacae*), and the *S. marcescens* strains, significant differences in activity were observed when DC-159a was tested against wild-type strains and various strains with defined mechanisms of resistance (Table 3). The DC-159a MIC<sub>90</sub>s for the wild-type strains ranged from 0.5 to 2 µg/ml, whereas they ranged from 1 to 8 µg/ml for the resistant subsets of strains. The activity of DC-159a was comparable to the activities of the other fluoroquinolones tested against these isolates of the family *Enterobacteriaceae*, regardless of the core-

TABLE 1. Activity of DC-159a tested by reference CLSI methods against 323 strains of streptococci and gram-negative pathogens associated with respiratory tract infections

Organism (no. of strains tested)/ antimicrobial agent	MIC (μg/ml)			% Susceptible/ % resistant <sup>a</sup> :
	50%	90%	Range	
<i>S. pneumoniae</i>				
Penicillin susceptible (30)				
DC-159a	0.12	0.12	0.06–0.25	– <sup>b</sup> /–
Gatifloxacin	0.25	0.25	0.06–0.5	100.0/0.0
Gemifloxacin	≤0.015	≤0.015	≤0.015–0.03	100.0/0.0
Levofloxacin	1	1	0.5–1	100.0/0.0
Moxifloxacin	0.12	0.12	≤0.03–0.25	100.0/0.0
Ciprofloxacin	1	2	0.25–2	–/–
Erythromycin	≤0.25	≤0.25	≤0.25–>32	96.7/3.3
Clindamycin	≤0.25	≤0.25	≤0.25–>2	96.7/3.3
Penicillin intermediate (30)				
DC-159a	0.06	0.12	0.06–0.12	–/–
Gatifloxacin	0.25	0.25	0.12–1	100.0/0.0
Gemifloxacin	≤0.015	0.03	≤0.015–0.06	100.0/0.0
Levofloxacin	1	1	0.5–1	100.0/0.0
Moxifloxacin	0.12	0.12	0.06–0.5	100.0/0.0
Ciprofloxacin	1	2	0.5–2	–/–
Erythromycin	2	>32	≤0.25–>32	43.3/53.3
Clindamycin	≤0.25	>2	≤0.25–>2	73.3/26.7
Penicillin resistant (32)				
DC-159a	0.12	0.12	0.06–0.12	–/–
Gatifloxacin	0.25	0.5	0.25–1	100.0/0.0
Gemifloxacin	≤0.015	0.03	≤0.015–0.03	100.0/0.0
Levofloxacin	1	1	0.5–2	100.0/0.0
Moxifloxacin	0.12	0.25	0.06–1	100.0/0.0
Ciprofloxacin	1	2	0.5–4	–/–
Erythromycin	4	>32	≤0.25–>32	37.5/62.5
Clindamycin	≤0.25	>2	≤0.25–>2	56.3/43.8
Levofloxacin nonsusceptible (20)				
DC-159a	0.5	1	0.25–2	–/–
Gatifloxacin	4	>4	1–>4	10.0/65.0
Gemifloxacin	0.12	0.25	≤0.06–1	65.0/10.0
Moxifloxacin	2	4	0.25–4	35.0/20.0
Ciprofloxacin	>4	>4	4–>4	–/–
Erythromycin	≤0.25	>2	≤0.25–>8	60.0/40.0
Clindamycin	≤0.25	>2	≤0.25–>2	75.0/20.0
β-Hemolytic streptococci				
Group A (30)				
DC-159a	0.12	0.12	0.06–0.12	–/–
Gatifloxacin	0.25	0.25	0.12–0.5	100.0/0.0
Gemifloxacin	0.015	0.03	0.008–0.06	–/–
Levofloxacin	0.5	1	0.25–2	100.0/0.0
Moxifloxacin	0.12	0.25	0.06–0.25	–/–
Ciprofloxacin	0.5	0.5	0.25–2	–/–
Penicillin	≤0.015	≤0.015	≤0.015	100.0/–
Erythromycin	≤0.06	4	≤0.06–>8	86.7/13.3
Clindamycin	≤0.06	≤0.06	≤0.06–>8	96.7/3.3
Group B (30)				
DC-159a	0.12	0.12	0.06–0.25	–/–
Gatifloxacin	0.25	0.25	0.12–0.5	100.0/0.0
Gemifloxacin	0.015	0.03	0.008–0.06	–/–
Levofloxacin	1	1	0.5–1	100.0/0.0
Moxifloxacin	0.12	0.25	0.06–0.25	–/–
Ciprofloxacin	0.5	1	0.25–1	–/–
Penicillin	0.06	0.12	≤0.015–0.12	100.0/–
Erythromycin	≤0.06	2	≤0.06–>8	76.7/23.3
Clindamycin	≤0.06	≤0.06	≤0.06–>8	90.0/10.0

Continued on following page

TABLE 1—Continued

Organism (no. of strains tested)/ antimicrobial agent	MIC (μg/ml)			% Susceptible/ % resistant <sup>a</sup> :
	50%	90%	Range	
<i>H. influenzae</i>				
β-Lactamase negative (40)				
DC-159a	0.008	0.015	0.008–0.015	–/–
Gatifloxacin	≤0.03	≤0.03	≤0.03	100.0/–
Gemifloxacin	≤0.015	≤0.015	≤0.015	100.0/–
Levofloxacin	0.015	0.015	≤0.008–0.03	100.0/–
Moxifloxacin	≤0.03	≤0.03	≤0.03	100.0/–
Ciprofloxacin	≤0.12	≤0.12	≤0.12	100.0/–
Amoxicillin-clavulanic acid	0.5	1	0.25–2	100.0/0.0
Azithromycin	1	2	≤0.5–>16	97.5/–
β-Lactamase positive (30)				
DC-159a	0.015	0.03	≤0.004–0.03	–/–
Gatifloxacin	≤0.03	≤0.03	≤0.03	100.0/–
Gemifloxacin	≤0.015	≤0.015	≤0.015	100.0/–
Levofloxacin	0.015	0.015	≤0.008–0.03	100.0/–
Moxifloxacin	≤0.03	≤0.03	≤0.03–0.06	100.0/–
Ciprofloxacin	≤0.12	≤0.12	≤0.12	100.0/–
Amoxicillin-clavulanic acid	≤1	≤1	≤1	100.0/0.0
Azithromycin	1	2	≤0.5–>4	96.7/–
β-Lactamase negative, ampicillin resistant (10) <sup>c</sup>				
DC-159a	0.015	0.015	0.008–0.015	–/–
Gatifloxacin	≤0.03	≤0.03	≤0.03	100.0/–
Gemifloxacin	≤0.12	≤0.12	≤0.12	100.0/–
Levofloxacin	0.015	0.015	0.015	100.0/–
Moxifloxacin	≤0.03	≤0.03	≤0.03	100.0/–
Ciprofloxacin	≤0.12	≤0.12	≤0.12	100.0/–
Ampicillin	2	2	2–4	0.0/10.0
Amoxicillin-clavulanic acid	4	4	2–8	90.0/10.0
Azithromycin	1	1	0.5–1	100.0/–
<i>H. parainfluenzae</i> (30)				
DC-159a	0.06	0.12	0.008–0.25	–/–
Gatifloxacin	≤0.03	≤0.03	≤0.03–0.12	100.0/–
Gemifloxacin	≤0.12	≤0.12	≤0.12	100.0/–
Levofloxacin	0.03	0.06	0.015–0.12	100.0/–
Moxifloxacin	≤0.03	0.12	≤0.03–0.5	100.0/–
Ciprofloxacin	≤0.25	≤0.25	≤0.25	100.0/–
Ampicillin	≤1	2	≤1–>4	86.7/10.0
Amoxicillin-clavulanic acid	≤2	≤2	≤2–4	100.0/0.0
Azithromycin	0.5	2	0.12–2	100.0/–
<i>M. catarrhalis</i>				
β-Lactamase negative (10)				
DC-159a	0.03	0.03	0.015–0.03	–/–
Gatifloxacin	≤0.03	≤0.03	≤0.03	–/–
Gemifloxacin	≤0.12	≤0.12	≤0.12	–/–
Levofloxacin	0.03	0.03	0.015–0.03	–/–
Moxifloxacin	0.06	0.06	≤0.03–0.06	–/–
Ciprofloxacin	≤0.12	≤0.12	≤0.12	–/–
Penicillin	≤0.03	≤0.03	≤0.03–0.06	–/–
Amoxicillin-clavulanic acid	≤0.06	≤0.06	≤0.06	–/–
Erythromycin	≤0.25	≤0.25	≤0.25	–/–
β-Lactamase positive (19)				
DC-159a	0.03	0.03	0.015–0.03	–/–
Gatifloxacin	≤0.03	≤0.03	≤0.03–0.06	–/–
Gemifloxacin	≤0.12	≤0.12	≤0.12	–/–
Levofloxacin	0.03	0.03	0.015–0.03	–/–
Moxifloxacin	0.06	0.06	≤0.03–0.06	–/–
Ciprofloxacin	≤0.12	≤0.12	≤0.12	–/–

Continued on following page

TABLE 1—Continued

Organism (no. of strains tested)/ antimicrobial agent	MIC ( $\mu\text{g/ml}$ )			% Susceptible/ % resistant <sup>a</sup> :
	50%	90%	Range	
Penicillin	2	>4	0.25–>4	–/–
Amoxicillin-clavulanic acid	$\leq 0.25$	$\leq 0.25$	$\leq 0.25$	–/–
Erythromycin	$\leq 0.25$	$\leq 0.25$	$\leq 0.25$	–/–
<i>B. pertussis</i> (12)				
DC-159a	0.008	0.015	0.008–0.015	–/–
Levofloxacin	0.06	0.06	0.03–0.06	100.0/0.0
Ciprofloxacin	0.03	0.03	0.015–0.03	100.0/0.0
Azithromycin	0.06	0.12	0.03–0.12	–/–
Clarithromycin	0.06	0.12	0.03–0.25	–/–
Erythromycin	0.12	0.12	0.06–0.25	–/–
Clindamycin	0.25	0.25	0.06–0.5	–/–

<sup>a</sup> Criteria published by the CLSI (4).

<sup>b</sup> –, no breakpoint criteria have been established for this category.

<sup>c</sup> Ampicillin at  $\geq 2 \mu\text{g/ml}$ , according to the definition of BLNAR.

sistance of the isolates analyzed (Table 3). Only the carbapenems (imipenem) and amikacin showed wider spectra of activity against these groups of the *Enterobacteriaceae*.

DC-159a was active (MIC<sub>50</sub> and MIC<sub>90</sub>, 0.06  $\mu\text{g/ml}$ ) against all wild-type isolates of *Salmonella* spp. at  $\leq 0.25 \mu\text{g/ml}$  (Table 3). This level of activity was equal to the levels of activity of all other fluoroquinolones tested. One strain had a CMY-2  $\beta$ -lactamase that produced resistance to extended-spectrum cepheims. Against the more resistant salmonellae, DC-159a MICs were four- to eightfold higher, consistent with a first-step QRDR mutation. All other fluoroquinolone MICs were similarly elevated, but none of the isolates were judged to be resistant according to the CLSI breakpoint criteria (4). The *Shigella* sp. isolates were very susceptible to DC-159a and all fluoroquinolones tested. The test results for strains of five other species of the *Enterobacteriaceae* (*Edwardsiella tarda* [one strain], *Escherichia vulneris* [two strains], *Hafnia alvei* [four strains], *Leclercia adecarboxylata* [one strain], *Pantoea agglomerans* [one strain], and *Serratia plymuthica* [one strain]) showed variable patterns of resistance among the organisms; however, DC-159a inhibited all isolates at  $\leq 1 \mu\text{g/ml}$  (MIC<sub>50</sub>, 0.06  $\mu\text{g/ml}$ ) (data not shown).

All *P. aeruginosa* isolates (30 strains; Table 3) were ciprofloxacin susceptible, with a single strain having a DC-159a and a gatifloxacin MIC of 4  $\mu\text{g/ml}$  (potential intermediate susceptibility); however, three strains (10% of strains) had moxifloxacin MICs of 4  $\mu\text{g/ml}$ . DC-159a was twofold less active than levofloxacin by use of the MIC<sub>50</sub> (0.5  $\mu\text{g/ml}$ ) and MIC<sub>90</sub> (2  $\mu\text{g/ml}$ ) results. Other than the fluoroquinolones, only the aminoglycosides inhibited more than 90% of the *P. aeruginosa* strains. Against the ciprofloxacin-resistant *P. aeruginosa* strains (10 strains), the DC-159a MICs ranged from 4 to  $>8 \mu\text{g/ml}$ . None of the fluoroquinolones tested were active, and only three of the antimicrobials tested (ceftazidime [which was active against 50% of the isolates], imipenem [50%], and amikacin [60%]) were active against  $\geq 50\%$  of these *P. aeruginosa* strains.

The activities of the fluoroquinolones (MIC<sub>90</sub>s) against the wild-type *Acinetobacter* sp. strains varied over a narrow range from 0.12  $\mu\text{g/ml}$  (DC-159a, gatifloxacin, moxifloxacin) to 0.25

$\mu\text{g/ml}$  (levofloxacin, ciprofloxacin). *Acinetobacter* resistant to the commonly used fluoroquinolones demonstrated cross-resistance and coresistance to  $\beta$ -lactams (except carbapenems) and some other drug classes. DC-159a was the most active of the agents tested against *S. maltophilia* (30 strains; Table 3).

The activity of DC-159a was compared to the activities of five agents against 60 gonococci with various ciprofloxacin susceptibility categories according to the CLSI (4) breakpoint criteria (Table 4). The DC-159a MICs increased (as did the levofloxacin MICs) as the ciprofloxacin MICs increased. The DC-159a MIC ranges for ciprofloxacin-susceptible, -intermediate, and -resistant strains were 0.008 to 0.015, 0.03 to 0.12, and 0.25 to 1  $\mu\text{g/ml}$ , respectively. The levels of resistance to the  $\beta$ -lactams and tetracycline were also elevated among the ciprofloxacin-resistant strains. Overall, the DC-159a MICs were greater than or equal to eightfold lower than those of ciprofloxacin or levofloxacin against gonococcal strains with mutations in the QRDR.

## DISCUSSION

The emergence of resistance to a wide range of antimicrobials among pathogens in medical centers and in the outpatient setting has posed serious therapeutic challenges. Examples of the most problematic pathogens have been (i) CA-MRSA strains, (ii) glycopeptide-nonsusceptible staphylococci, (iii) MDR *P. aeruginosa* and *Acinetobacter* sp. strains, (iv) vancomycin-resistant enterococci, (v) strains with novel  $\beta$ -lactamases with wide substrate affinities, and (vi) MDR *S. pneumoniae* strains (1, 6, 12–14). Concurrent with this resistance has been the introduction of several newer fluoroquinolones (10) primarily directed against community-acquired respiratory tract infections and novel drug classes (oxazolidinones) that are active among resistant gram-positive pathogens (5). These introductions have been associated with evolving resistance due to ribosomal target and QRDR mutations (11, 12). The QRDR mutations in *S. pneumoniae* elevate the MICs of the currently available fluoroquinolone to levels associated with clinical failure (7), and similar QRDR modifications in *S. aureus* (8) present therapeutic obstacles to the use of existing



TABLE 2. Antimicrobial activity of DC-159a against 283 strains of other gram-positive species isolates by CLSI methods

Organism (no. of strains tested)/antimicrobial agent	MIC (μg/ml)			% Susceptible/ % resistant <sup>a</sup>
	50%	90%	Range	
<i>S. aureus</i>				
Oxacillin susceptible (30)				
DC-159a	0.03	0.03	0.015–0.06	– <sup>b</sup> /–
Gatifloxacin	0.06	0.12	≤0.03–0.12	100.0/0.0
Levofloxacin	0.12	0.25	0.06–0.25	100.0/0.0
Moxifloxacin	≤0.03	0.06	≤0.03–0.12	100.0/0.0
Ciprofloxacin	0.25	0.5	0.06–0.5	100.0/0.0
Linezolid	1	2	0.5–2	100.0/–
Tetracycline	≤2	4	≤2–>8	90.0/10.0
Trimethoprim-sulfamethoxazole	≤0.5	≤0.5	≤0.5	100.0/0.0
Clindamycin	0.12	0.12	≤0.06–0.5	100.0/0.0
Erythromycin	0.25	>8	0.25–>8	83.3/16.7
Oxacillin resistant, nosocomial (30)				
DC-159a	1	2	0.5–4	–/–
Gatifloxacin	4	>4	1–>4	0.0/96.7
Levofloxacin	>8	>8	4–>8	0.0/100.0
Moxifloxacin	2	4	1–>4	0.0/83.3
Ciprofloxacin	>4	>4	>4	0.0/100.0
Linezolid	1	2	1–2	100.0/–
Tetracycline	≤2	>8	≤2–>8	80.0/20.0
Trimethoprim-sulfamethoxazole	≤0.5	>2	≤0.5–>2	86.7/13.3
Clindamycin	>8	>8	≤0.06–>8	26.7/70.0
Erythromycin	>8	>8	0.25–>8	6.7/93.3
Oxacillin resistant, community acquired (30)				
DC-159a	0.03	0.03	0.008–0.5	–/–
Gatifloxacin	0.06	0.12	≤0.03–2	93.3/6.7
Levofloxacin	0.12	0.25	0.12–4	93.3/6.7
Moxifloxacin	≤0.03	0.06	≤0.03–1	93.3/0.0
Ciprofloxacin	≤0.25	0.5	≤0.25–>4	93.3/6.7
Linezolid	2	2	1–2	100.0/–
Tetracycline	≤4	≤4	≤4–>8	90.0/10.0
Trimethoprim-sulfamethoxazole	≤0.5	≤0.5	≤0.5	100.0/0.0
Clindamycin	0.12	0.12	≤0.06–0.25	100.0/0.0
Erythromycin	>8	>8	>8	0.0/100.0
CoNS (30) <sup>c</sup>				
DC-159a	0.06	0.5	0.03–0.5	–/–
Gatifloxacin	0.25	2	0.06–4	60.0/16.7
Levofloxacin	0.25	8	0.12–8	60.0/26.7
Moxifloxacin	0.25	2	≤0.03–4	63.3/16.7
Ciprofloxacin	0.5	>4	0.12–>4	56.7/43.3
Linezolid	1	1	0.5–2	100.0/–
Tetracycline	≤2	>8	≤2–>8	86.7/13.3
Trimethoprim-sulfamethoxazole	≤0.5	>2	≤0.5–>2	66.7/33.3
Clindamycin	≤0.06	>8	≤0.06–>8	83.3/16.7
Erythromycin	0.25	>8	≤0.06–>8	53.3/43.3
Oxacillin	2	>2	≤0.25–>2	30.0/70.0
<i>S. saprophyticus</i> (30)				
DC-159a	0.12	0.25	0.03–0.5	–/–
Gatifloxacin	0.25	2	0.06–2	83.3/13.3
Levofloxacin	0.5	2	0.12–8	86.7/10.0
Moxifloxacin	0.12	1	≤0.03–2	83.3/6.7
Ciprofloxacin	0.5	>4	0.12–>4	83.3/16.7
Linezolid	1	2	0.5–2	100.0/–
Tetracycline	≤2	>8	≤2–>8	76.7/23.3
Trimethoprim-sulfamethoxazole	≤0.5	>2	≤0.5–>2	86.7/13.3
Clindamycin	≤0.06	0.5	≤0.06–>8	90.0/10.0
Erythromycin	0.25	>8	0.12–>8	60.0/40.0
Oxacillin	1	>2	0.5–>2	0.0/100.0

Continued on following page

TABLE 2—Continued

Organism (no. of strains tested)/antimicrobial agent	MIC (μg/ml)			% Susceptible/ % resistant <sup>a</sup>
	50%	90%	Range	
<i>E. faecalis</i>				
Vancomycin susceptible (30)				
DC-159a	0.12	4	0.06–>8	–/–
Gatifloxacin	0.25	>4	0.12–>4	80.0/20.0
Levofloxacin	0.5	>8	0.25–>8	80.0/20.0
Ciprofloxacin	0.5	>4	0.25–>4	80.0/20.0
Ampicillin	≤1	2	≤1–4	100.0/0.0
Linezolid	1	2	0.5–2	100.0/0.0
Gentamicin-HL	≤500	>1000	≤500–>1000	70.0/30.0
Tetracycline	>8	>8	≤2–>8	23.3/76.7
Erythromycin	2	>8	0.25–>8	13.3/46.7
Vancomycin resistant (30)				
DC-159a	4	4	0.12–8	–/–
Gatifloxacin	>4	>4	0.12–>4	6.7/93.3
Levofloxacin	>8	>8	0.5–>8	6.7/93.3
Ciprofloxacin	>4	>4	0.5–>4	6.7/93.3
Ampicillin	2	4	≤1–16	96.7/3.3
Linezolid	1	2	1–2	100.0/0.0
Gentamicin-HL <sup>c</sup>	>1000	>1000	≤500–>1000	30.0/70.0
Tetracycline	>8	>8	≤2–>8	33.3/66.7
Erythromycin	>8	>8	2–>8	0.0/96.7
<i>Enterococcus faecium</i>				
Vancomycin susceptible (31)				
DC-159a	1	>8	0.06–>8	–/–
Gatifloxacin	2	>4	0.25–>4	51.6/45.2
Levofloxacin	2	>8	0.25–>8	51.6/45.2
Ciprofloxacin	4	>4	0.25–>4	25.8/58.1
Ampicillin	>16	>16	≤1–>16	41.9/58.1
Linezolid	2	2	1–2	100.0/0.0
Gentamicin-HL	≤500	>1000	≤500–>1000	77.4/22.6
Tetracycline	≤2	>8	≤2–>8	58.1/38.7
Erythromycin	>8	>8	0.25–>8	6.5/67.7
Vancomycin resistant (32)				
DC-159a	8	>8	0.25–>8	–/–
Gatifloxacin	>4	>4	0.5–>4	18.8/81.3
Levofloxacin	>8	>8	2–>8	18.8/81.3
Ciprofloxacin	>4	>4	1–>4	3.1/87.5
Ampicillin	>16	>16	2–>16	3.1/96.9
Linezolid	2	2	1–2	100.0/0.0
Gentamicin-HL	≤500	>1000	≤500–>1000	65.6/34.4
Tetracycline	>8	>8	≤2–>8	40.6/59.4
Erythromycin	>8	>8	1–>8	0.0/87.5
<i>Enterococcus</i> spp., linezolid resistant (10) <sup>d</sup>				
DC-159a	4	>8	2–>8	–/–
Gatifloxacin	>4	>4	>4	0.0/100.0
Levofloxacin	>8	>8	>8	0.0/100.0
Ciprofloxacin	>4	>4	>4	0.0/100.0
Ampicillin	≤1	>16	≤1–>16	50.0/50.0
Vancomycin	>16	>16	0.5–>16	40.0/60.0
Gentamicin-HL	≤500	>1000	≤500–>1000	60.0/40.0
Tetracycline	>8	>8	≤2–>8	30.0/70.0
Erythromycin	>8	>8	2–>8	0.0/90.0

<sup>a</sup> Criteria published by the CLSI (4). The determination of  $\beta$ -lactam susceptibility should be directed by the oxacillin test results.<sup>b</sup> –, no breakpoint criteria have been established for this category.<sup>c</sup> CoNS include *Staphylococcus auricularis* (four strains), *S. capitis* (three strains), coagulase-negative staphylococcus (one strain), *S. cohnii* (one strain), *S. epidermidis* (five strains), *S. haemolyticus* (three strains), *S. hominis* (two strains), *S. intermedius* (two strains), *S. lugdunensis* (two strains), *S. schleiferi* (one strain), *S. sciuri* (one strain), *S. simulans* (one strain), *S. warneri* (two strains), and *S. xylois* (two strains).<sup>d</sup> Includes *Enterococcus faecalis* (five strains) and *E. faecium* (five strains).<sup>e</sup> HL, high level.

TABLE 3. Activity of DC-159a against 423 strains of gram-negative bacilli by reference (CLSI) methods

Organism (no. of strains tested)/ antimicrobial agent	MIC (μg/ml)			% Susceptible/ % resistant <sup>a</sup>
	50%	90%	Range	
<i>E. coli</i>				
Wild type (20)				
DC-159a	0.03	0.12	0.015–8	– <sup>b</sup> /–
Gatifloxacin	≤0.03	0.12	≤0.03–>4	90.0/5.0
Gemifloxacin	0.008	0.06	0.004–>2	90.0/10.0
Levofloxacin	0.03	0.25	0.015–8	90.0/5.0
Moxifloxacin	≤0.03	0.25	≤0.03–>4	–/–
Ciprofloxacin	≤0.03	0.12	≤0.03–>4	90.0/10.0
Ceftriaxone	≤0.25	≤0.25	≤0.25–16	95.0/0.0
Imipenem	≤0.5	≤0.5	≤0.5	100.0/0.0
Amikacin	2	2	0.5–4	100.0/0.0
ESBL phenotype (20) <sup>c</sup>				
DC-159a	0.06	>8	0.015–>8	–/–
Gatifloxacin	≤0.03	>4	≤0.03–>4	70.0/20.0
Gemifloxacin	≤0.03	>1	≤0.03–>1	65.0/35.0
Levofloxacin	0.06	>8	0.015–>8	65.0/25.0
Moxifloxacin	0.06	>4	≤0.03–>4	–/–
Ciprofloxacin	≤0.25	>2	≤0.25–>2	65.0/35.0
Ceftriaxone	16	>32	1–>32	40.0/20.0
Imipenem	0.25	0.5	≤0.12–0.5	100.0/0.0
Amikacin	2	16	0.5–16	100.0/0.0
<i>Klebsiella</i> spp.				
Wild type (20) <sup>d</sup>				
DC-159a	0.12	1	0.03–8	–/–
Gatifloxacin	0.06	1	≤0.03–>4	90.0/5.0
Gemifloxacin	0.03	0.5	0.015–>2	85.0/10.0
Levofloxacin	0.06	1	0.03–8	90.0/5.0
Moxifloxacin	0.12	1	0.06–>4	–/–
Ciprofloxacin	≤0.03	0.5	≤0.03–>4	90.0/10.0
Ceftriaxone	≤0.25	32	≤0.25–>32	85.0/10.0
Imipenem	≤0.5	≤0.5	≤0.5	100.0/0.0
Amikacin	1	8	0.5–32	95.0/0.0
ESBL phenotype (20) <sup>e</sup>				
DC-159a	0.5	>8	0.06–>8	–/–
Gatifloxacin	0.5	>4	≤0.03–>4	65.0/20.0
Gemifloxacin	0.25	>1	0.015–>1	55.0/40.0
Levofloxacin	1	>8	0.03–>8	65.0/30.0
Moxifloxacin	0.5	>4	0.06–>4	–/–
Ciprofloxacin	1	>2	≤0.015–>2	55.0/40.0
Ceftriaxone	32	>32	4–>32	15.0/45.0
Imipenem	≤0.5	≤0.5	≤0.5–1	100.0/0.0
Amikacin	16	>32	1–>32	65.0/25.0
KPC producers (10) <sup>f</sup>				
DC-159a	>8	>8	0.06–>8	–/–
Gatifloxacin	>4	>4	≤0.03–>4	20.0/80.0
Gemifloxacin	>2	>2	0.015–>2	10.0/90.0
Levofloxacin	>8	>8	0.03–>8	20.0/80.0
Moxifloxacin	>4	>4	0.06–>4	–/–
Ciprofloxacin	>4	>4	≤0.03–>4	10.0/90.0
Ceftriaxone	>32	>32	16–>32	0.0/80.0
Imipenem	>8	>8	4–>8	10.0/60.0
Amikacin	32	>32	4–>32	30.0/30.0
<i>P. mirabilis</i> (20) <sup>g</sup>				
DC-159a	0.25	>8	0.12–>8	–/–
Gatifloxacin	0.5	>4	0.06–>4	75.0/20.0
Gemifloxacin	0.25	>2	0.03–>2	55.0/45.0
Levofloxacin	0.12	>8	0.03–>8	85.0/15.0
Moxifloxacin	1	>4	0.12–>4	–/–
Ciprofloxacin	0.12	>2	≤0.03–>2	65.0/15.0

Continued on following page



TABLE 3—Continued

Organism (no. of strains tested)/ antimicrobial agent	MIC (μg/ml)			% Susceptible/ % resistant <sup>a</sup>
	50%	90%	Range	
Ceftriaxone	≤0.25	32	≤0.25–>32	80.0/10.0
Imipenem	1	2	≤0.5–4	100.0/0.0
Amikacin	4	4	2–>32	95.0/5.0
<i>Citrobacter</i> spp.				
Wild type (20) <sup>h</sup>				
DC-159a	0.06	0.5	0.03–8	–/–
Gatifloxacin	≤0.03	0.5	≤0.03–4	90.0/0.0
Gemifloxacin	0.015	0.25	0.004–>2	90.0/10.0
Levofloxacin	0.03	0.5	0.015–8	90.0/5.0
Moxifloxacin	0.06	1	≤0.03–>4	–/–
Ciprofloxacin	≤0.03	0.5	≤0.03–>4	90.0/10.0
Ceftriaxone	≤0.25	4	≤0.25–8	100.0/0.0
Imipenem	≤0.5	1	≤0.5–1	100.0/0.0
Amikacin	1	2	0.5–4	100.0/0.0
Ceftazidime resistant (10) <sup>i</sup>				
DC-159a	0.12	1	0.06–2	–/–
Gatifloxacin	0.5	4	≤0.03–>4	80.0/10.0
Gemifloxacin	0.03	1	0.008–2	70.0/20.0
Levofloxacin	0.06	1	0.03–4	90.0/0.0
Moxifloxacin	1	>4	0.06–>4	–/–
Ciprofloxacin	0.12	4	≤0.03–>4	80.0/20.0
Ceftriaxone	32	>32	16–>32	0.0/20.0
Imipenem	≤0.5	1	≤0.5–4	100.0/0.0
Amikacin	2	4	1–>32	90.0/10.0
<i>Enterobacter</i> spp.				
Wild type (20) <sup>j</sup>				
DC-159a	0.06	0.5	0.03–>8	–/–
Gatifloxacin	≤0.03	0.12	≤0.03–>4	95.0/5.0
Gemifloxacin	0.015	0.06	0.008–>2	95.0/5.0
Levofloxacin	0.03	0.12	0.015–>8	95.0/5.0
Moxifloxacin	0.06	0.25	≤0.03–>4	–/–
Ciprofloxacin	≤0.03	0.06	≤0.03–>4	95.0/5.0
Ceftriaxone	≤0.25	0.5	≤0.25–>32	95.0/5.0
Imipenem	≤0.5	≤0.5	≤0.5–1	100.0/0.0
Amikacin	1	2	1–16	100.0/0.0
Ceftazidime resistant (13) <sup>k</sup>				
DC-159a	0.5	8	0.06–8	–/–
Gatifloxacin	0.5	>4	≤0.03–>4	69.2/30.8
Gemifloxacin	0.12	>2	0.008–>2	76.9/23.1
Levofloxacin	0.25	>8	0.03–>8	76.9/23.1
Moxifloxacin	0.5	>4	0.06–>4	–/–
Ciprofloxacin	0.25	>4	≤0.03–>4	61.5/30.8
Ceftriaxone	>32	>32	4–>32	23.1/61.5
Imipenem	≤0.5	2	≤0.5–4	100.0/0.0
Amikacin	2	8	0.5–>32	92.3/7.7
Indole-positive <i>Proteae</i> (40) <sup>l</sup>				
DC-159a	0.25	8	0.06–>8	–/–
Gatifloxacin	0.12	>4	≤0.03–>4	75.0/20.0
Gemifloxacin	0.06	>2	0.004–>2	70.0/30.0
Levofloxacin	0.06	8	0.03–>8	75.0/20.0
Moxifloxacin	0.25	>4	0.06–>4	–/–
Ciprofloxacin	≤0.03	>4	≤0.03–>4	72.5/27.5
Ceftriaxone	≤0.25	4	≤0.25–32	92.5/0.0
Imipenem	1	2	≤0.5–4	100.0/0.0
Amikacin	2	4	0.5–16	100.0/0.0

Continued on following page

TABLE 3—Continued

Organism (no. of strains tested)/ antimicrobial agent	MIC ( $\mu$ g/ml)			% Susceptible/ % resistant <sup>a</sup>
	50%	90%	Range	
<i>S. marcescens</i>				
Wild type (20)				
DC-159a	0.5	2	0.12–8	–/–
Gatifloxacin	0.25	2	0.12–>4	90.0/5.0
Gemifloxacin	0.12	1	0.06–>2	75.0/20.0
Levofloxacin	0.12	1	0.06–4	90.0/0.0
Moxifloxacin	0.5	4	0.25–>4	–/–
Ciprofloxacin	0.06	1	0.06–>4	90.0/10.0
Ceftriaxone	$\leq 0.25$	2	$\leq 0.25$ –>32	90.0/5.0
Imipenem	$\leq 0.5$	1	$\leq 0.5$ –2	100.0/0.0
Amikacin	4	32	1–>32	85.0/5.0
Ceftazidime resistant (10)				
DC-159a	2	8	0.25–8	–/–
Gatifloxacin	2	>4	0.12–>4	50.0/30.0
Gemifloxacin	1	>2	0.03–>2	30.0/60.0
Levofloxacin	1	8	0.12–8	60.0/30.0
Moxifloxacin	2	>4	0.12–>4	–/–
Ciprofloxacin	1	>4	0.06–>4	50.0/50.0
Ceftriaxone	32	>32	16–>32	0.0/50.0
Imipenem	$\leq 0.5$	1	$\leq 0.5$ –1	100.0/0.0
Amikacin	32	>32	2–>32	30.0/30.0
<i>Salmonella</i> spp.				
Wild type (20) <sup>m</sup>				
DC-159a	0.06	0.06	0.015–0.25	–/–
Gatifloxacin	$\leq 0.03$	0.06	$\leq 0.03$ –0.25	100.0/0.0
Gemifloxacin	0.015	0.015	0.004–0.12	100.0/0.0
Levofloxacin	0.03	0.06	0.015–0.25	100.0/0.0
Moxifloxacin	0.06	0.12	$\leq 0.03$ –0.5	–/–
Ciprofloxacin	$\leq 0.03$	$\leq 0.03$	$\leq 0.03$ –0.25	100.0/0.0
Ceftriaxone	$\leq 0.25$	$\leq 0.25$	$\leq 0.25$ –16	95.0/0.0
Imipenem	$\leq 0.5$	$\leq 0.5$	$\leq 0.5$	100.0/0.0
Amikacin	1	2	1–4	100.0/0.0
Resistant phenotype (10) <sup>n</sup>				
DC-159a	0.25	0.5	0.06–1	–/–
Gatifloxacin	0.12	0.5	$\leq 0.03$ –1	100.0/0.0
Gemifloxacin	0.06	0.25	$\leq 0.008$ –0.25	100.0/0.0
Levofloxacin	0.25	0.5	0.03–1	100.0/0.0
Moxifloxacin	0.25	1	0.03–2	–/–
Ciprofloxacin	0.12	0.25	$\leq 0.03$ –1	100.0/0.0
Ceftriaxone	$\leq 0.25$	32	$\leq 0.25$ –32	70.0/0.0
Imipenem	$\leq 0.5$	$\leq 0.5$	$\leq 0.5$	100.0/0.0
Amikacin	2	2	1–2	100.0/0.0
<i>Shigella</i> spp. (40) <sup>o</sup>				
DC-159a	0.03	0.06	0.015–0.25	–/–
Gatifloxacin	$\leq 0.03$	$\leq 0.03$	$\leq 0.03$ –0.25	100.0/0.0
Gemifloxacin	0.008	0.015	0.004–0.12	100.0/0.0
Levofloxacin	0.03	0.06	0.015–0.25	100.0/0.0
Moxifloxacin	$\leq 0.03$	0.06	$\leq 0.03$ –0.25	–/–
Ciprofloxacin	$\leq 0.03$	$\leq 0.03$	$\leq 0.03$ –0.25	100.0/0.0
Ceftriaxone	$\leq 0.25$	$\leq 0.25$	$\leq 0.25$	100.0/0.0
Imipenem	$\leq 0.5$	$\leq 0.5$	$\leq 0.5$	100.0/0.0
Amikacin	4	4	1–8	100.0/0.0
<i>P. aeruginosa</i>				
Wild type (30)				
DC-159a	0.5	2	0.25–4	–/–
Gatifloxacin	0.5	1	0.12–4	96.7/0.0
Levofloxacin	0.25	1	0.12–2	100.0/0.0
Moxifloxacin	1	2	0.25–4	–/–

Continued on following page

TABLE 3—Continued

Organism (no. of strains tested)/ antimicrobial agent	MIC (μg/ml)			% Susceptible/ % resistant <sup>a</sup>
	50%	90%	Range	
Ciprofloxacin	0.12	0.25	≤0.03–1	100.0/0.0
Ceftazidime	2	16	≤1–>16	86.7/6.7
Cefepime	2	16	1–>16	86.7/6.7
Imipenem	1	>8	≤0.5–>8	83.3/13.3
Amikacin	2	4	0.5–>32	93.3/3.3
Ciprofloxacin resistant (10)				
DC-159a	>8	>8	4–>8	–/–
Gatifloxacin	>4	>4	4–>4	0.0/90.0
Levofloxacin	>8	>8	8–>8	0.0/100.0
Ciprofloxacin	>4	>4	4–>4	0.0/100.0
Ceftazidime	4	>16	2–>16	50.0/40.0
Cefepime	16	>16	8–>16	40.0/20.0
Imipenem	2	>8	≤0.5–>8	50.0/40.0
Amikacin	8	>32	2–>32	60.0/40.0
<i>Acinetobacter</i> spp.				
Wild type (30) <sup>p</sup>				
DC-159a	0.06	0.12	0.015–1	–/–
Gatifloxacin	≤0.03	0.12	≤0.03–0.5	100.0/0.0
Levofloxacin	0.06	0.25	0.03–0.5	100.0/0.0
Ciprofloxacin	0.12	0.25	0.06–0.5	100.0/0.0
Ceftazidime	4	16	≤1–>16	76.7/10.0
Cefepime	2	16	0.25–>16	86.7/6.7
Imipenem	≤0.5	≤0.5	≤0.5–4	100.0/0.0
Amikacin	2	8	≤0.25–>32	93.3/6.7
Ciprofloxacin and levofloxacin resistant (10) <sup>q</sup>				
DC-159a	8	>8	4–>8	–/–
Gatifloxacin	>4	>4	4–>4	0.0/90.0
Levofloxacin	>8	>8	8–>8	0.0/100.0
Ceftazidime	>16	>16	8–>16	10.0/80.0
Cefepime	16	>16	16–>16	0.0/50.0
Imipenem	1	>8	≤0.5–>8	80.0/20.0
Amikacin	16	>32	4–>32	50.0/40.0
<i>S. maltophilia</i> (30)				
DC-159a	0.12	0.5	0.03–4	–/–
Gatifloxacin	0.5	2	0.12–>4	90.0/6.7
Levofloxacin	0.5	2	0.06–>8	93.3/6.7
Ciprofloxacin	1	4	0.25–>4	53.3/16.7
Ceftazidime	8	>16	≤1–>16	50.0/43.3
Cefepime	>16	>16	4–>16	20.0/56.7
Amikacin	>32	>32	4–>32	6.7/86.7

<sup>a</sup> Criteria published by the CLSI (4).<sup>b</sup> –, no breakpoint criteria have been established for this category or agent.<sup>c</sup> Includes strains harboring TEM-1, TEM-3, TEM-4, TEM-5, TEM-6, TEM-7, TEM-8, SHV-5, CTX-M2, CMY-2 (8 strains), or FOX-5 (3 strains).<sup>d</sup> Includes *Klebsiella oxytoca* (5 strains) and *K. pneumoniae* (15 strains).<sup>e</sup> Includes *Klebsiella pneumoniae* (20 strains) with mobile AmpC enzymes (9 strains), CTX-M2 (4 strains), SHV-5 (5 strains), SHV-7, and ESBL NOS.<sup>f</sup> Includes *Klebsiella pneumoniae* (10 strains) harboring KPC NOS (4 strains), KPC-2 (5 strains), or KPC-3 (11 strains).<sup>g</sup> CTX-M phenotypes (two strains).<sup>h</sup> Includes *Citrobacter braakii* (1 strain), *C. farmeri* (1 strain), *C. freundii* (11 strains), and *C. koseri* (7 strains).<sup>i</sup> Includes *Citrobacter freundii* (nine strains), and *Citrobacter* species (one strain).<sup>j</sup> Includes *Enterobacter aerogenes* (4 strains) and *E. cloacae* (16 strains).<sup>k</sup> Includes *Enterobacter aerogenes* (1 strain), *E. cloacae* (10 strains), *E. gergoviae* (1 strain), and *Enterobacter* species (1 strain).<sup>l</sup> Includes *Morganella morganii* (10 strains), *Proteus vulgaris* (11 strains), *Providencia rettgeri* (9 strains), and *Providencia stuartii* (10 strains).<sup>m</sup> Includes *Salmonella* group B (three strains), *Salmonella* group C (two strains), *Salmonella* group D (two strains), *Salmonella* species (eight strains), *Salmonella enterica* serovar Typhi (two strains), and *S. enterica* serovar Typhimurium (three strains).<sup>n</sup> Resistance to ampicillin, cephalosporins, tetracyclines, or trimethoprim-sulfamethoxazole. Includes *S. enterica* serovar Enteritidis (one strain), *Salmonella* group B (one strain), *Salmonella* group C (one strain), *S. enterica* serovar Hadar (one strain), *S. enterica* serovar Heidelberg (one strain), *S. enterica* serovar Typhi (one strain), *S. enterica* serovar Typhimurium (three strains), and *S. enterica* serovar Virchow (one strain).<sup>o</sup> Includes *Shigella boydii* (4 strains), *S. dysenteriae* (3 strains), *S. flexneri* (14 strains), *S. sonnei* (16 strains), and *Shigella* species (3 strains).<sup>p</sup> Includes *Acinetobacter anitratus* (1 strain), *A. baumannii* (14 strains), *A. calcoaceticus* (3 strains), *A. junii* (2 strains), *A. lwoffii* (8 strains), and *Acinetobacter* species (2 strains).<sup>q</sup> Includes *Acinetobacter baumannii* (nine strains) and *A. lwoffii* (one strain).

TABLE 4. Activity of DC-159a against 60 *N. gonorrhoeae* strains by the reference agar dilution method

Organism group (no. of strains tested) and antimicrobial agent	MIC (μg/ml)			% Susceptible/ % resistant <sup>a</sup>
	50%	90%	Range	
Ciprofloxacin susceptible (20)				
DC-159a	0.015	0.015	0.008–0.015	– <sup>b</sup> /–
Levofloxacin	0.015	0.03	0.008–0.03	100.0/0.0
Ciprofloxacin	≤0.008	0.015	≤0.008–0.015	100.0/0.0
Ceftriaxone	≤0.008	0.015	≤0.008–0.06	100.0/–
Penicillin	0.25	1	0.015–>4	35.0/10.0
Tetracycline	0.25	1	0.12–2	55.0/10.0
Ciprofloxacin intermediate (25)				
DC-159a	0.12	0.12	0.03–0.12	–/–
Levofloxacin	0.25	0.5	0.12–0.5	0.0/0.0
Ciprofloxacin	0.25	0.5	0.12–0.5	0.0/0.0
Ceftriaxone	0.03	0.06	≤0.008–0.12	100.0/–
Penicillin	2	>4	0.5–>4	0.0/88.0
Tetracycline	1	2	0.5–2	0.0/48.0
Ciprofloxacin resistant (15)				
DC-159a	1	1	0.25–1	–/–
Levofloxacin	4	8	2–8	0.0/100.0
Ciprofloxacin	>4	>4	2–>4	0.0/100.0
Ceftriaxone	0.015	0.06	≤0.008–0.06	100.0/–
Penicillin	2	>4	1–>4	0.0/80.0
Tetracycline	2	>4	0.25–>4	6.7/73.3

<sup>a</sup> Criteria published by the CLSI (4). The criteria for ofloxacin were applied to levofloxacin for comparison purposes only.

<sup>b</sup> –, no breakpoint criteria have been established for this category or drug.

fluoroquinolones for the treatment of CA-MRSA or other MRSA infections. Furthermore, the use of fluoroquinolones as the treatment of choice for uncomplicated gonorrhea has been negated by the high rates of resistance among gonococci in the United States and worldwide (16).

In this study of the activity of DC-159a, DC-159a was shown to possess a combination of antimicrobial qualities that may overcome some of the deficiencies of current fluoroquinolones, confirming the findings of earlier studies (2, 9). Against levofloxacin- or penicillin-resistant *S. pneumoniae* strains, DC-159a had activity (MIC<sub>90</sub> range, 0.12 to 1  $\mu\text{g/ml}$ ) intermediate between that of gemifloxacin (MIC<sub>90</sub> range, 0.03 to 0.25  $\mu\text{g/ml}$ ) and that of moxifloxacin (MIC<sub>90</sub> range, 0.25 to 4  $\mu\text{g/ml}$ ), and DC-159a was also very potent against other species associated with community-acquired respiratory tract infections (MIC range, 0.015 to 0.12; MICs for all strains,  $\leq 0.25$   $\mu\text{g/ml}$ ). DC-159a was approximately 16-fold more active than ciprofloxacin against staphylococci and showed the potential for use for the treatment of endemic CA-MRSA strains and some mutants with QRDR mutations. Gonococci resistant or intermediately susceptible to ciprofloxacin had DC-159a MICs that ranged from 0.03 to 1  $\mu\text{g/ml}$ . Finally, the overall potency of DC-159a against members of the family *Enterobacteriaceae* (median MIC<sub>50</sub>, 0.12  $\mu\text{g/ml}$ ), *P. aeruginosa* (MIC<sub>50</sub> for wild-type strains, 0.5  $\mu\text{g/ml}$ ), and *Acinetobacter* spp. (MIC<sub>50</sub> for wild-type strains, 0.06  $\mu\text{g/ml}$ ) was most similar to that of levofloxacin, although DC-159a was markedly more active against the *S. maltophilia* strains (MIC<sub>50</sub>, 0.12  $\mu\text{g/ml}$ ). We eagerly await the publication of pharmacokinetic/pharmacodynamic results for DC-159a so that predictive microbiological/clinical breakpoint concentrations can be assigned (4, 15).

#### ACKNOWLEDGMENTS

We thank the following technical staff at JMI Laboratories for their contributions to the study and manuscript preparation: N. O'Mara-Morrissey, D. J. Biedenbach, P. R. Rhomberg, G. Moet, and K. Fedler.

The study was funded by an educational/research grant from Daiichi Pharmaceutical Co., Ltd.

#### REFERENCES

- Bratu, S., D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam, and J. Quale. 2005. Rapid spread of carbapenem-resistant *Klebsiella pneumoniae* in New York City: a new threat to our antibiotic armamentarium. *Arch. Intern. Med.* **165**:1430–1435.
- Clark, C., K. Smith, L. Ednie, T. Bogdanovich, B. Dewasse, P. McGhee, and P. C. Appelbaum. 2008. In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. *Antimicrob. Agents Chemother.* **52**:77–84.
- Clinical and Laboratory Standards Institute. 2006. M7-A7, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. 2008. M100-S18. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
- Diekema, D. L., and R. N. Jones. 2000. Oxazolidinones: a review. *Drugs* **59**:7–16.
- Diekema, D. J., B. J. BootsMiller, T. E. Vaughn, R. F. Woolson, J. W. Yankey, E. J. Ernst, S. D. Flach, M. M. Ward, C. L. Francis, M. A. Pfaller, and B. N. Doebbeling. 2004. Antimicrobial resistance trends and outbreak frequency in United States hospitals. *Clin. Infect. Dis.* **38**:78–85.
- Fuller, J. D., and D. E. Low. 2005. A review of *Streptococcus pneumoniae* infection treatment failures associated with fluoroquinolone resistance. *Clin. Infect. Dis.* **41**:118–121.
- Horii, T., Y. Suzuki, A. Monji, M. Morita, H. Muramatsu, Y. Kondo, M. Doi, A. Takeshita, T. Kanno, and M. Maekawa. 2003. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant *Staphylococcus aureus*: effects of the mutations on fluoroquinolone MICs. *Diagn. Microbiol. Infect. Dis.* **46**:139–145.
- Hoshino, K., K. Inoue, Y. Murakami, Y. Kurosaka, K. Namba, Y. Kashimoto, S. Uoyama, R. Okumura, S. Higuchi, and T. Otani. 2008. In vitro and

- in vivo antibacterial activities of DC-159a, a new fluoroquinolone. *Antimicrob. Agents Chemother.* **52**:65–76.
10. **Jones, R. N.** 2004. Susceptibility trends in respiratory pathogens: the role of the newer fluoroquinolones. *Consultant* **44**:S5–S13.
  11. **Mutnick, A. H., V. Enne, and R. N. Jones.** 2003. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. *Ann. Pharmacother.* **37**:769–774.
  12. **Pottumarthy, S., T. R. Fritsche, and R. N. Jones.** 2005. Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant *Streptococcus pneumoniae*: report from the SENTRY Antimicrobial Surveillance Program (1997–2003). *Diagn. Microbiol. Infect. Dis.* **51**:147–150.
  13. **Rice, L. B.** 2006. Challenges in identifying new antimicrobial agents effective for treating infections with *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *Clin. Infect. Dis.* **43**(Suppl. 2):S100–S105.
  14. **Ruef, C.** 2004. Epidemiology and clinical impact of glycopeptide resistance in *Staphylococcus aureus*. *Infection* **32**:315–327.
  15. **Schurek, K. N., H. J. Adam, D. J. Hoban, and G. G. Zhanel.** 2006. Call for the international adoption of microbiological breakpoints for fluoroquinolones and *Streptococcus pneumoniae*. *Int. J. Antimicrob. Agents* **28**:266–269.
  16. **Wang, S. A., A. B. Harvey, S. M. Conner, A. A. Zaidi, J. S. Knapp, W. L. Whittington, C. del Rio, F. N. Judson, and K. K. Holmes.** 2007. Antimicrobial resistance for *Neisseria gonorrhoeae* in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. *Ann. Intern. Med.* **147**:81–88.